Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11 -Hydroxysteroid Dehydrogenase Type 1 (11 -HSD1) Inhibitor: Discovery of 2-[(3S)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017)
Scott, J.S., Bowker, S.S., Deschoolmeester, J., Gerhardt, S., Hargreaves, D., Kilgour, E., Lloyd, A., Mayers, R.M., McCoull, W., Newcombe, N.J., Ogg, D., Packer, M.J., Rees, A., Revill, J., Schofield, P., Selmi, N., Swales, J.G., Whittamore, P.R.(2012) J Med Chem 55: 5951-5964
- PubMed: 22691057 
- DOI: https://doi.org/10.1021/jm300592r
- Primary Citation of Related Structures:  
4HFR - PubMed Abstract: 
Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. We report here the discovery of a nicotinic amide derived carboxylic acid class of inhibitors that has good potency, selectivity, and pharmacokinetic characteristics. Compound 11i (AZD4017) is an effective inhibitor of 11β-HSD1 in human adipocytes and exhibits good druglike properties and as a consequence was selected for clinical development.
Organizational Affiliation: 
Cardiovascular and Gastrointestinal Innovative Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. jamie.scott@astrazeneca.com